Illumina posts mixed earnings report while dealing with China tariff fallout
The DNA sequencing giant said it will continue to do business in China as long as it’s able—while also dealing with a decline in annual revenues.
The DNA sequencing giant said it will continue to do business in China as long as it’s able—while also dealing with a decline in annual revenues.
